Suzhou Zelgen Biopharmaceuticals Co Ltd Strategic Asset Allocation Index
Suzhou Zelgen Biopharmaceuticals Co Ltd strategic asset allocation index. Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a Strategic Asset Allocation Index of 13.4% as of June 2023. Strategic assets (PP&E of CN¥246.14 Million plus long-term investments of CN¥-) total CN¥246.14 Million, measured against net assets of CN¥1.84 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See 688266 net asset quality score to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2022)
Strategic asset allocation index of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2022. This chart shows how Suzhou Zelgen Biopharmaceuticals Co Ltd's Strategic Asset Allocation Index has evolved across 7 annual periods from 2016 to 2022. As of June 2023, the index stands at 13.4%, representing strategic assets of CN¥246.14 Million against net assets of CN¥1.84 Billion CNY. Check Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Suzhou Zelgen Biopharmaceuticals Co Ltd Strategic Asset Allocation Index by Year (2016–2022)
Suzhou Zelgen Biopharmaceuticals Co Ltd strategic asset allocation index by year from 2016 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2022, covering 7 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market cap of Suzhou Zelgen Biopharmaceuticals Co Ltd.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 31.4% | CN¥247.09 Million | CN¥247.09 Million | CN¥- | CN¥787.49 Million | ▲ +16.3 pp |
| 2021 | 15.1% | CN¥188.91 Million | CN¥188.91 Million | CN¥- | CN¥1.25 Billion | ▲ +9.7 pp |
| 2020 | 5.4% | CN¥91.03 Million | CN¥91.03 Million | CN¥- | CN¥1.69 Billion | ▼ -71.5 pp |
| 2019 | 76.8% | CN¥56.67 Million | CN¥56.67 Million | CN¥- | CN¥73.75 Million | ▲ +56.6 pp |
| 2018 | 20.2% | CN¥56.98 Million | CN¥56.98 Million | CN¥- | CN¥281.64 Million | ▼ -43.9 pp |
| 2017 | 64.1% | CN¥46.81 Million | CN¥46.81 Million | CN¥- | CN¥73.02 Million | ▲ +31.7 pp |
| 2016 | 32.4% | CN¥35.46 Million | CN¥35.46 Million | CN¥- | CN¥109.44 Million | — |